MXPA01008349A - Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide. - Google Patents

Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.

Info

Publication number
MXPA01008349A
MXPA01008349A MXPA01008349A MXPA01008349A MXPA01008349A MX PA01008349 A MXPA01008349 A MX PA01008349A MX PA01008349 A MXPA01008349 A MX PA01008349A MX PA01008349 A MXPA01008349 A MX PA01008349A MX PA01008349 A MXPA01008349 A MX PA01008349A
Authority
MX
Mexico
Prior art keywords
intravenous
pharmaceutical formulation
intramuscular
octreotide
octreotide administration
Prior art date
Application number
MXPA01008349A
Other languages
English (en)
Inventor
Ponsati Obiols Berta
Original Assignee
Lipotec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipotec Sa filed Critical Lipotec Sa
Publication of MXPA01008349A publication Critical patent/MXPA01008349A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulacion Farmaceutica Estable para la administracion intravenosa o intramuscular de Octeotride que se caracteriza porque como vehiculo para la inyeccion del peptido o sus sales farmaceuticamente aceptables, contiene Glicina en concentraciones de 10 mM y solucion acuosa de acido clorhidrico en una cantidad suficiente para ajustar el pH de la formulacion a valores entre 3,0 y 4,2.
MXPA01008349A 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide. MXPA01008349A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009902769A ES2167189B1 (es) 1999-12-17 1999-12-17 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
PCT/ES2000/000476 WO2001043776A1 (es) 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide

Publications (1)

Publication Number Publication Date
MXPA01008349A true MXPA01008349A (es) 2004-03-19

Family

ID=8310959

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008349A MXPA01008349A (es) 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.

Country Status (13)

Country Link
US (1) US6521599B2 (es)
EP (1) EP1153615B1 (es)
JP (1) JP4912551B2 (es)
AT (1) ATE233105T1 (es)
AU (1) AU763779B2 (es)
BR (1) BR0008249A (es)
CA (1) CA2362772C (es)
DE (1) DE60001489T2 (es)
DK (1) DK1153615T3 (es)
ES (2) ES2167189B1 (es)
MX (1) MXPA01008349A (es)
PT (1) PT1153615E (es)
WO (1) WO2001043776A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293196A1 (en) * 2002-12-23 2004-07-29 Vical Incorporated Method for producing sterile polynucleotide based medicaments
PE20050285A1 (es) 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
JP2010538092A (ja) * 2007-09-07 2010-12-09 ユナイテッド セラピューティクス コーポレーション グラム陰性菌に対して選択的殺菌活性を有するバッファー溶液およびそれを使用する方法
CN102416001B (zh) * 2011-12-09 2013-06-05 重庆煜澍丰医药有限公司 一种注射用醋酸奥曲肽冻干粉针剂及其制备方法
CN111346214A (zh) * 2020-05-13 2020-06-30 吉林吉力生物技术研究有限公司 一种动物注射用醋酸奥曲肽冻干粉针剂及其制备方法和应用
CN114146054B (zh) * 2020-09-07 2022-12-02 深圳市健元医药科技有限公司 一种醋酸奥曲肽注射液的制备工艺
CN114288385B (zh) * 2021-12-27 2024-01-19 苏州天马医药集团天吉生物制药有限公司 一种醋酸奥曲肽制剂的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
TW249202B (es) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
AU3257297A (en) * 1996-06-11 1998-01-07 Novartis Ag Combination of a somatostatin analogue and a rapamycin

Also Published As

Publication number Publication date
AU763779B2 (en) 2003-07-31
BR0008249A (pt) 2001-10-30
ES2193114T3 (es) 2003-11-01
DK1153615T3 (da) 2003-06-23
DE60001489D1 (de) 2003-04-03
CA2362772A1 (en) 2001-06-21
US6521599B2 (en) 2003-02-18
ES2167189A1 (es) 2002-05-01
WO2001043776A1 (es) 2001-06-21
PT1153615E (pt) 2003-06-30
ES2167189B1 (es) 2003-04-01
JP4912551B2 (ja) 2012-04-11
AU2173601A (en) 2001-06-25
JP2003517024A (ja) 2003-05-20
CA2362772C (en) 2010-03-16
ATE233105T1 (de) 2003-03-15
EP1153615B1 (en) 2003-02-26
US20020128204A1 (en) 2002-09-12
EP1153615A1 (en) 2001-11-14
DE60001489T2 (de) 2003-12-04

Similar Documents

Publication Publication Date Title
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
WO2002015903A3 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
HK1054196A1 (en) Pharmaceutical formulation containing tolterodine and its use
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
WO2003093299A3 (en) Insulin-associated peptides with effects on cerebral health
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
HUP0202749A2 (hu) Levoszimendánt tartalmazó oldat formájú gyógyszerkészítmény
MXPA01008349A (es) Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
MY132911A (en) Clear, injectable solution of an anesthetic compound
YU8701A (sh) Nova oralna kompozicija
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
AU2003211474A1 (en) Stabilized albumin preparaions
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
WO2005018657A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
WO2001068676A3 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzeimittel
Hussain et al. An aminoboronic acid derivative inhibits thymopentin metabolism by mucosal membrane aminopeptidases
ES2242973T3 (es) Utilizacion de antagonistas peptidicos de bradiquinina para la preparacion de medicamentos.
WO2005019457A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
WO2005019448A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
MY152490A (en) New oral formulation

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
PD Change of proprietorship

Owner name: GP PHARM, S.A.*